Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 8 Publications

2 Customer Reviews

  • (f and g) Induction of apoptosis in HMC-1.1 and -1.2, respectively. Columns represent the mean of three independent experiments and the bars represent the standard error. ctrl, control; mido, midostaurin.

    Leukemia, 2018, 32(1):139-148. Midostaurin (PKC412) purchased from Selleck.

    PKC412 is cytotoxic to human HNSCC cells. The established HNSCC cells (SQ20B and SCC‐9 cell lines), primary human oral carcinoma cells (“Primary1/2”) and primary oral epithelial cells (“Epithelial”), were treated with indicated concentrations of PKC412. Cells were then cultured in complete medium for the applied time, and cell survival was tested by the MTT assay (a, d) and colony formation assay (c). Cell death was tested by the trypan blue staining assay (b). “CTR” indicates medium‐treated control group (for all figures). All the experiments were repeated five times, and similar results were obtained. n = 5 for each assay. Error bars indicate mean ± SD (for all figures). *p < 0.05 versus group “CTR.” HNSCC, head and neck squamous cell carcinoma; MTT, 3‐(4,5‐dimethyl‐thiazol-2-yl)2,5-diphenyl tetrazolium bromide; OD, optical density; PKC, protein kinase C

    J Cell Physiol, 2018, 233(12):9437-9446. Midostaurin (PKC412) purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells NWDtcZR{S3m2b4TvfIlkcXS7IHHzd4F6 MUO3NkBp MmrjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGGodHXyJFczKGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVA:OTJibl2= Mn\XNVk3PTR2MEi=
RS4-11 cells MYDGeY5kfGmxbjDhd5NigQ>? Mor0NkBp M2XRXmlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iUmO0MVEyKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHXs[YN1em:laHXtbYx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3ME2xN{BvVQ>? NWXVT3NnOTl4NUS0NFg>
CGTH-W-1 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlL0TY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQzNjZ3IN88US=> M1POR3NCVkeHUh?=
SW982 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWHJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NEWuOVgh|ryP MWPTRW5ITVJ?
human EoL-1-cell cell NFjvRZBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYHJcohq[mm2aX;uJI9nKGi3bXHuJGVwVC1zLXPlcIwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Oi5yODDuUS=> MoXvV2FPT0WU
MOLM-13 cells NYj2blNkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnjOO|IhcA>? M3zCNGlvcGmkaYTpc44hd2ZiRlzUN{BKXERiaHX0[ZJwgnmpb4XzJI12fGGwdDDpckBpfW2jbjDNU2xONTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VWyCjc4PhfUwhT0l3ME2wMlA2PSEQvF2= M3m2SFI3ODhzMEKz
KASUMI-1 cell M3;IVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1zNRWlvcGmkaYTpc44hd2ZiaIXtZY4hU0GVVV3JMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MEG2JO69VQ>? NHfIO4lUSU6JRWK=
NCI-H1755 cell M2DRV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe1OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODZ{N{Og{txO MlH4V2FPT0WU
human MES-SA cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXrTfpN6UW6qaXLpeIlwdiCxZjDoeY1idiCPRWOtV2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB5NUS0JO69VQ>? NV60XVEzW0GQR1XS
human HCC1395 cell NInIfphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVfJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF|OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PDJ6IN88US=> NFXMZo5USU6JRWK=
human D-336MG cell NHfHdYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml3YTY5pcWKrdHnvckBw\iCqdX3hckBFNTN|Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDd3NDFOwG0> M37XfHNCVkeHUh?=
CHP-212 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF3YV4VKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB6N{ezJO69VQ>? NYWw[oZDW0GQR1XS
human KM12 cell MkTTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXvEWlBFUW6qaXLpeIlwdiCxZjDoeY1idiCNTUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQTJ5NTFOwG0> NEfWR5NUSU6JRWK=
A204 cell Mk\vS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXThcVBUUW6qaXLpeIlwdiCxZjDoeY1idiCDMkC0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yODB3MjFOwG0> M1Hyd3NCVkeHUh?=
CAL-51 cell M172e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3HuOGlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yODdyOTFOwG0> M3m0S3NCVkeHUh?=
human A431 cell NV3ublVxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYfySFB4UW6qaXLpeIlwdiCxZjDoeY1idiCDNEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTJzNjFOwG0> MlG0V2FPT0WU
NCI-H650 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVHZfGtWUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUG3NFgh|ryP MmW1V2FPT0WU
A427 cell M2jqfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\TNHVKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyQTF6IN88US=> NFLwbZBUSU6JRWK=
human 769-P cell Mn7ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3j6cmlvcGmkaYTpc44hd2ZiaIXtZY4hPzZ7LWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzODh{IN88US=> MXHTRW5ITVJ?
SW1710 cell MknqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3TJUmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOzNzNjFOwG0> M{XOcnNCVkeHUh?=
human H4 cell MmfxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXvJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zM{m2N{DPxE1? MlPXV2FPT0WU
HT-1080 cell NGTJcWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnTKTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPTl6MjFOwG0> NGi1Uo1USU6JRWK=
human PANC-03-27 cell NH;TWoFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3jJSGlvcGmkaYTpc44hd2ZiaIXtZY4hWEGQQz2wN{0zPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMU[wNkDPxE1? NFnsdWVUSU6JRWK=
A375 cells NEewU2hEgXSxdH;4bYNqfHliYYPzZZk> NIXRcZI4OiCq MX;Uc5hq[2m2eTDh[4FqdnO2IHj1cYFvKEF|N{WgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygTWM2OD1yLkG4JO69VQ>? NUXofFBQOTl4NUS0NFg>
human HOP-62 cell Mn\2SpVv[3Srb36gZZN{[Xl? MkjSTY5pcWKrdHnvckBw\iCqdX3hckBJV1BvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE5ODd|IN88US=> M1T1S3NCVkeHUh?=
human U031 cell NXjrOnZ1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoH0TY5pcWKrdHnvckBw\iCqdX3hckBWODNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xPVY6QCEQvF2= NGXwU4FUSU6JRWK=
mouse BAF3 cells M3jINXBzd2yrZnXyZZRqd25iYYPzZZk> NHfXNYlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgeJJidnOob4Lt[YQhf2m2aDDaUmYyQThvRlfGVlEh[2:wc4TyeYN1NCCLQ{WwQVAvOiEQvF2= NF\UbHAzOTl|NkW0Ni=>
human G-402 cell NWnTSY95T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUW3bGFLUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjB{NUOg{txO M2G0OXNCVkeHUh?=
human G-361 cell NHXIOnlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1K0U2lvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIxQDV|IN88US=> NXPNXIl3W0GQR1XS
NCI-H810 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoewTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjFyMkeg{txO NHvFT4VUSU6JRWK=
NCI-H2030 cell NFzvdVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkCzNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjNyME[g{txO MUDTRW5ITVJ?
human HCT-116 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1PKSWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN3Nkig{txO M3zye3NCVkeHUh?=
human SNU-423 cell NH:wemNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mnu1TY5pcWKrdHnvckBw\iCqdX3hckBUVlVvNEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzZ3NzFOwG0> M3yzXnNCVkeHUh?=
human SCC-4 cell M2C3dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{LrVWlvcGmkaYTpc44hd2ZiaIXtZY4hW0OFLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{QTZ5IN88US=> NIPSZXFUSU6JRWK=
human SW48 cell M1TkT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkTxTY5pcWKrdHnvckBw\iCqdX3hckBUXzR6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yOlY5KM7:TR?= M1f4fXNCVkeHUh?=
human SF295 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVHnV5o{UW6qaXLpeIlwdiCxZjDoeY1idiCVRkK5OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjd{NUeg{txO MmS4V2FPT0WU
MDA-MB-231 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHTkcZhKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0zOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkK4NVAyKM7:TR?= NXHpUHpFW0GQR1XS
A172 cell NGDYblJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHjsenlKdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI6OTVizszN NG\WbIVUSU6JRWK=
human BCPAP cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M17IUGlvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI6QDd7IN88US=> NEnoZnhUSU6JRWK=
human COLO-792 cell M4DRXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3i4dmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ7OUeyJO69VQ>? MkfXV2FPT0WU
human DU-145 cell NWmzS3NxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|E5QDlizszN Mkf0V2FPT0WU
NCI-H2122 cell NV\UdnR4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXP3eWJrUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIyOjJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOyNlg2KM7:TR?= NHjiS5hUSU6JRWK=
human SK-UT-1 cell MmrQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVTnTWpKUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|Mkm1NkDPxE1? MVPTRW5ITVJ?
LXF-289 cell M4\6RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXvJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTZ3IN88US=> M3j6[XNCVkeHUh?=
human NCI-H1792 cell M1\YVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4jsS2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|M{C5OkDPxE1? NUD5bpVKW0GQR1XS
MCF7 cell NFjZeZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{PTdWlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|MzPzRizszN M2[2U3NCVkeHUh?=
HCT-15 cell M2DIbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M1OzJizszN MoWyV2FPT0WU
human NCI-H358 cell NGf5SYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KM{W4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzV3MTFOwG0> MWrTRW5ITVJ?
human HLE cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{PhWWlvcGmkaYTpc44hd2ZiaIXtZY4hUEyHIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zN|c2OiEQvF2= NECyeIlUSU6JRWK=
human SW1088 cell MoS2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFztPY1KdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN5OUeg{txO NIDZSoxUSU6JRWK=
human K5 cell Mmn5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn7ETY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{[xOFkh|ryP MUfTRW5ITVJ?
human SR cell M3:4ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmDmTY5pcWKrdHnvckBw\iCqdX3hckBUWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{[1O|Eh|ryP MUDTRW5ITVJ?
human Calu-3 cell NYraNZBwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M13ZfGlvcGmkaYTpc44hd2ZiaIXtZY4hS2GudT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{Pjh{NTFOwG0> MljHV2FPT0WU
human SK-MEL-30 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mo\xTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN7OUGzJO69VQ>? Mkf0V2FPT0WU
human SW780 cell NVjFb3ppT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NG\RSWFKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTF2MjFOwG0> NXjMcpI{W0GQR1XS
NCI-H1563 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3HsNWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MUS4OEDPxE1? MWfTRW5ITVJ?
human MKN45 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3LqeGlvcGmkaYTpc44hd2ZiaIXtZY4hVUuQNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQyQTNzIN88US=> M{PWcXNCVkeHUh?=
MDA-MB-157 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFe4SnpKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0yPTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSyNFE2KM7:TR?= MljPV2FPT0WU
human NCI-H522 cell NYLQN2dMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHzXc4NKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkOg{txO NIXY[GxUSU6JRWK=
human A2780 cell NVzXc5pQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{XLUGlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4PTB|IN88US=> M4TMVHNCVkeHUh?=
human A498 cell NYD6bZcxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX7iWpZOUW6qaXLpeIlwdiCxZjDoeY1idiCDNEm4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PzZ7MzFOwG0> MY\TRW5ITVJ?
human BxPC-3 cell M{XLdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVHJcohq[mm2aX;uJI9nKGi3bXHuJGJ5WENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFk{PjZizszN NHTFZnZUSU6JRWK=
human A2058 cell NGT5elhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXHJcohq[mm2aX;uJI9nKGi3bXHuJGEzODV6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61Nlg1PCEQvF2= MVvTRW5ITVJ?
human PC-14 cell NFjRXlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NULmZW9WUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTN6NUWg{txO M3zBVXNCVkeHUh?=
human KG-1 cell Ml\mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2HIfmlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVU1OTlizszN NWXONGo6W0GQR1XS
human A375 cell MoLnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkW2NVA{KM7:TR?= M2nDUHNCVkeHUh?=
human SW1783 cell NVi3SJFuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{G3S2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{izJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OzN5IN88US=> M1P0dHNCVkeHUh?=
human MKN1 cell NHHRNppIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml\ITY5pcWKrdHnvckBw\iCqdX3hckBOU05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64PFQyOiEQvF2= M2nx[HNCVkeHUh?=
NCI-H1650 cell NX60U29nT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NI\oT49KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEi5NVbkiIEQvF2= MnfmV2FPT0WU
human HT-1376 cell M3rYTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{PuS2lvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUO3OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTJ7MUig{txO MWDTRW5ITVJ?
SW872 cell M2raPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1HsPGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk1PDV7IN88US=> MlzpV2FPT0WU
human RT-112 cell M331Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2LocGlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PzR6MzFOwG0> MnjEV2FPT0WU
human HT-29 cell NYLoe2dlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUjJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65O|k6PiEQvF2= M3PENnNCVkeHUh?=
human U-266 cell M4XsZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkjWTY5pcWKrdHnvckBw\iCqdX3hckBWNTJ4NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVg{ODJizszN NYP4UXo6W0GQR1XS
human HEL cell NWLhfWZUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmrrTY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm4OVE4KM7:TR?= NVO2eFZ7W0GQR1XS
human KU812 cell NH3hS4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4jLR2lvcGmkaYTpc44hd2ZiaIXtZY4hU1V6MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlEyOTZ2IN88US=> Ml\PV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03836209 Not yet recruiting Acute Myeloid Leukemia PrECOG LLC.|Astellas Pharma Inc July 2019 Phase 2
NCT03836209 Not yet recruiting Acute Myeloid Leukemia PrECOG LLC.|Astellas Pharma Inc July 2019 Phase 2
NCT03760445 Not yet recruiting Leukemia Myeloid Acute Novartis Pharmaceuticals|Novartis February 28 2019 Phase 1|Phase 2
NCT03760445 Not yet recruiting Leukemia Myeloid Acute Novartis Pharmaceuticals|Novartis February 28 2019 Phase 1|Phase 2
NCT03591510 Not yet recruiting FLT3-mutated Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis December 28 2018 Phase 2
NCT03591510 Not yet recruiting FLT3-mutated Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis December 28 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products0

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID